As a result, CD8+ TIL scoring is utilized in melanoma to quantify CD8+ TILs in the TME via standardized systems, such as those established by the Melanoma Institute of Australia (MIA; a score-based system on the density of CD8+ T-cells in the tumor center and invasive margin, as well as their distribution throughout the tumor) and Clark and colleagues (Clark system distinguishing three distinct CD8+ TILs patterns as absent, non-brisk, and brisk) [17]. This evidence concerns the gene CD8A and melanoma.